Veligrotug Biosimilar – Anti-CD221 mAb – Research Grade

Description of Veligrotug Biosimilar - Anti-CD221 mAb - Research Grade

Introduction

Veligrotug Biosimilar – Anti-CD221 mAb – Research Grade, also known as Veligrotug, is a monoclonal antibody (mAb) that targets the CD221 protein. This biosimilar is a highly specific and potent therapeutic agent that has shown promising results in preclinical studies. In this article, we will discuss the structure, activity, and potential applications of Veligrotug in the field of antibody-based therapeutics.

Structure of Veligrotug

Veligrotug is a recombinant humanized IgG1 monoclonal antibody that is produced using advanced genetic engineering techniques. It consists of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 50 kDa. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL’) and one variable domain (VL). The VH and VL domains together form the antigen-binding site of the antibody, which specifically recognizes and binds to the CD221 protein.

Activity of Veligrotug

CD221, also known as insulin-like growth factor 1 receptor (IGF-1R), is a transmembrane protein that is overexpressed in various types of cancer cells. It plays a crucial role in promoting cell survival, proliferation, and metastasis. Veligrotug specifically targets and binds to the extracellular domain of CD221, thereby inhibiting its downstream signaling pathways. This leads to the inhibition of cancer cell growth and survival, making Veligrotug a potentially effective therapeutic agent for the treatment of CD221-positive cancers.

Application of Veligrotug

Veligrotug is currently being investigated for its potential in the treatment of various types of cancer, including breast, lung, and prostate cancer. Preclinical studies have shown promising results in inhibiting tumor growth and inducing cell death in CD221-positive cancer cells. In addition to its direct anti- cancer activity, Veligrotug has also been shown to enhance the effectiveness of other cancer therapies, such as chemotherapy and radiation therapy. This is due to its ability to sensitize cancer cells to these treatments, making them more susceptible to their effects.

Furthermore, Veligrotug has also shown potential in the treatment of other diseases that are associated with CD221 overexpression, such as diabetes and autoimmune disorders. In diabetes, CD221 plays a role in insulin resistance and glucose metabolism, and Veligrotug has been shown to improve insulin sensitivity and regulate blood glucose levels in preclinical studies. In autoimmune disorders, CD221 has been implicated in the regulation of immune responses, and Veligrotug has shown potential in modulating these responses and reducing inflammation.

Conclusion

In summary, Veligrotug Biosimilar – Anti-CD221 mAb – Research Grade is a promising therapeutic agent with a highly specific and potent activity against CD221-positive cancers. Its unique structure and mechanism of action make it a potential treatment option for various types of cancer, as well as other diseases associated with CD221 overexpression. Further clinical studies are needed to fully evaluate the safety and efficacy of Veligrotug, but early results are promising and suggest that it may have a significant impact on the field of antibody-based therapeutics.